Freenome, Inc. Common stock Net Assets
Freenome, Inc. Common stock net assets. Based on the latest financial reports, Freenome, Inc. Common stock (FRNM) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Freenome, Inc. Common stock (FRNM) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Freenome, Inc. Common stock (2024–2025)
Net assets of Freenome, Inc. Common stock from 2024 to 2025. This chart illustrates how Freenome, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. See Freenome, Inc. Common stock (FRNM) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Freenome, Inc. Common stock (2024–2025)
The table below shows the annual net assets of Freenome, Inc. Common stock from 2024 to 2025. For live market cap and overall valuation, see market value of Freenome, Inc. Common stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.26 Billion | -19.73% |
| 2024-12-31 | $-1.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Freenome, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21934300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Freenome, Inc. Common stock Net Assets Breakdown (December 2025)
Freenome, Inc. Common stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $83.97 Million | % |
| Total Equity | $-1.26 Billion | 100.00% |
Freenome, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Freenome, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inox Wind Energy Limited
NSE:IWEL
|
$1.34 Billion |
|
Orora Ltd
AU:ORA
|
$1.34 Billion |
|
VGI Public Company Limited
BK:VGI-R
|
$1.34 Billion |
|
Geo-Jade Petroleum Corp
SHG:600759
|
$1.34 Billion |
|
BlackRock ESG Capital Allocation Trust
NYSE:ECAT
|
$1.34 Billion |
|
Med Life SA
RO:M
|
$1.34 Billion |
|
Sun Art Retail Group Limited
F:SRI
|
$1.34 Billion |
|
Aura Investments Ltd
TA:AURA
|
$1.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Freenome, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,055,017,000 to -1,263,136,000, a change of -208,119,000.
- Net loss of 219,343,000 reduced equity.
- Other factors increased equity by 11,224,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-219.34 Million | -17.36% |
| Other Changes | $11.22 Million | +0.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Freenome, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-9.94 | $12.48 | x |
| 2025-12-31 | $-11.91 | $12.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Freenome, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -721.31%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | -9521.89% | 0.01x | 0.00x | $-168.92 Million |
| 2025 | 0.00% | -721.31% | 0.06x | 0.00x | $-93.03 Million |
Industry Comparison
This section compares Freenome, Inc. Common stock's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $413,102,559
- Average return on equity (ROE) among peers: -440.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Freenome, Inc. Common stock (FRNM) | $- | 0.00% | N/A | $1.34 Billion |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $43.76 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $3.80 Million |
| Applied DNA Sciences Inc (APDN) | $1.94 Million | -3578.71% | 1.29x | $3.99 Million |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $245.37 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $13.09 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.66 Billion |
| Burning Rock Biotech Ltd (BNR) | $-603.46 Million | 0.00% | 0.00x | $96.07 Million |
| CareDx Inc (CDNA) | $-150.67 Million | 0.00% | 0.00x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Freenome, Inc. Common stock
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease det… Read more